Reuters logo
BRIEF-China Biologic receives approval for commercial manufacturing of human fibrinogen
October 9, 2017 / 1:07 PM / 2 months ago

BRIEF-China Biologic receives approval for commercial manufacturing of human fibrinogen

Oct 9 (Reuters) - China Biologic Products Holdings Inc

* China Biologic receives approval for commercial manufacturing of human fibrinogen

* China Biologic Products Holdings Inc - ‍expects first batch of products to be released to market by end of 2017​

* China Biologic Products Holdings Inc - ‍expect to see meaningful profit contribution from fibrinogen in 2018​

* China Biologic Products Holdings - unit received approval from China food and drug administration for commercial manufacturing of human fibrinogen Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below